Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
November 2024
in “
Pediatric Dermatology
”
TLDR Selumetinib causes fewer and less severe skin issues in children than binimetinib.
The study found that dermatologic adverse events are common in children using MEK inhibitors, with age being a factor in the likelihood of certain skin reactions. Patients taking selumetinib experienced less severe adverse events and had a lower risk of needing dose reduction or holding the medication compared to those on binimetinib. These findings can help clinicians offer better counseling, treatments, and preventive care for children undergoing MEK inhibitor therapy.